Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 18/20 | 0.81 |
| ▸ | TACR2 | P21452 | 9/20 | 0.81 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.80 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5636703 | 1.00 | TACR3 (0.81) | TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL5635546 | 0.95 | TACR3 (0.76) | TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL8116231 | 0.95 | TACR3 (0.76) | TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL6228533 | 0.89 | TACR3 (0.84) | TACR3TACR2OPRM1 | |
| SCHEMBL5636316 | 0.89 | TACR3 (0.84) | TACR3TACR2OPRM1 | |
| SCHEMBL6228536 | 0.89 | TACR3 (0.84) | TACR3TACR2OPRM1 | |
| SCHEMBL5636312 | 0.89 | TACR3 (0.84) | TACR3TACR2OPRM1 | |
| SCHEMBL5636960 | 0.88 | TACR3 (1.00) | TACR3TACR2OPRM1 | |
| SCHEMBL7692817 | 0.88 | TACR3 (0.83) | TACR3TACR2OPRM1 | |
| SCHEMBL5635855 | 0.88 | TACR3 (0.83) | TACR3TACR2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | claimed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM SPA, ITALY | 2007-08-23 | — | — | US | disclosed |
| US-20060205735-A1 | Quinoline-4-carboxamide as NK-2 and NK-3 receptor antagonists | MARIA GLARDINA GIUSEPPE A | 2006-09-14 | — | — | US | disclosed |
| US-20050159428-A1 | Quinoline-4-carboxamide derivatives asNK-2 and NK-3 receptor antagonists | SMITHKLINE BEECHAM SPA, ITALY | 2005-07-21 | — | — | US | disclosed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040116469-A1 | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists | SMITHKLINE BEECHAM SPA | 2004-06-17 | — | — | US | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-0983262-B1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2003-07-09 | — | — | EP | disclosed |
| US-20030004183-A1 | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists | GIARDINA GIUSEPPE ARNALDO MARI (IT) | 2003-01-02 | — | — | US | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20010012846-A1 | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists | GLARDINA GIUSEPPE ARNALDO MARI (IT) | 2001-08-09 | — | — | US | disclosed |
| CN-1264378-A | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists | SMITHKLINE BEECHAM SPA (IT) | 2000-08-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TACR3 86/4885TACR2 7/4885OPRM1 81/4885 |
| US-20030004183-A1 | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists | KCNH2, KCNH3, KCNA6 | TACR3 130/4885TACR2 34/4885OPRM1 67/4885 |
| US-20060205735-A1 | Quinoline-4-carboxamide as NK-2 and NK-3 receptor antagonists | KCNJ2, KCNH2, KCNH3 | TACR3 25/4885TACR2 10/4885OPRM1 301/4885 |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | KCNH2, KCNH3, KCNJ2 | TACR3 27/4885TACR2 8/4885OPRM1 259/4885 |
| US-20010012846-A1 | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists | KCNH2, KCNH3, KCNA6 | TACR3 137/4885TACR2 36/4885OPRM1 64/4885 |
| US-20050159428-A1 | Quinoline-4-carboxamide derivatives asNK-2 and NK-3 receptor antagonists | KCNK3, KCNJ2, KCNK2 | TACR3 10/4885TACR2 4/4885OPRM1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.